Help protect a generation from future risk

Only GARDASIL—
helps protect against multiple HPV types

^†AIS=adenocarcinoma in situ.
^‡CIN=cervical intraepithelial neoplasia.

GARDASIL is a vaccine indicated in girls and women 9 to 26 years of age for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by HPV Types 6, 11, 16, and 18.

> Learn how to help protect girls and young women.

Select safety information

GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine.

Vaccination with GARDASIL may not result in protection in all vaccine recipients.

GARDASIL is not intended to be used for treatment of active genital warts; cervical cancer; cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.

GARDASIL does not substitute for routine cervical cancer screening, and women who receive GARDASIL should continue to undergo screening per standard of care.

GARDASIL has not been shown to protect against diseases due to non-vaccine HPV types.

The duration of protection of GARDASIL is unknown at present. GARDASIL will not protect against diseases that are not caused by HPV.

The vaccine-related adverse experiences that were observed among recipients of GARDASIL at a frequency of at least 1.0% and greater than placebo were pain, swelling, erythema, fever, nausea, pruritus, and dizziness. In addition, common postmarketing reports include vomiting and syncope.

As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine.

A complete vaccination regimen of GARDASIL consists of a 3-dose schedule. See Safety and Tolerability and Dosage and Administration.

Before administering GARDASIL, please read the Prescribing Information and Patient Product Information.

GARDASIL is a registered trademark of Merck & Co., Inc.